EPA vs DHA: Does the Ratio in Your Omega-3 Supplement Matter?

Two fish-oil bottles can both say 1,000 mg on the front and still deliver very different amounts of the omega-3 fatty acids researchers actually study.

Then there is another number to interpret:

the EPA-to-DHA ratio.

One product might contain substantially more EPA. Another might lean toward DHA. Others provide roughly comparable amounts of each.

A new 2026 systematic review and meta-analysis makes that distinction more interesting. Across 96 clinical trials, researchers found that the EPA:DHA ratio was associated with different changes in blood fatty-acid profiles and several inflammatory markers.

That does not mean researchers have discovered one perfect omega-3 ratio.

It means the ratio is a real product specification — and potentially more useful than the large “fish oil” number printed on the front of the bottle.

EPA vs DHA: the evidence at a glance

EPA and DHA are both omega-3s, but they are not interchangeable

Most omega-3 discussions group EPA and DHA together.

That is useful up to a point.

Both are long-chain omega-3 fatty acids found primarily in marine foods and supplements such as fish oil and algal oil.

But they are chemically distinct.

EPA stands for eicosapentaenoic acid.

DHA stands for docosahexaenoic acid.

DHA is particularly prominent in tissues such as the brain and retina, while EPA and DHA both participate in pathways involving cell membranes, lipid mediators and cardiovascular risk factors.

This is why a supplement label that says only “omega-3” tells us less than a label that reports EPA and DHA separately.

Bextera’s omega-3 ingredient dossier treats EPA and DHA as separate product-comparison fields rather than assuming every milligram of fish oil is equivalent.

A 2026 meta-analysis examined the ratio directly

A 2026 systematic review and meta-analysis analyzed 96 clinical trials published before February 2025.

Rather than looking only at total omega-3 intake, the researchers examined the relationship between:

• the EPA:DHA ratio in supplements;
• total EPA+DHA intake;
• blood EPA and DHA levels;
• arachidonic acid;
• inflammatory markers including CRP, TNF-alpha and IL-6.

The analysis found that supplementation changed blood EPA:DHA ratios in ways related to the ratio being consumed.

That may sound obvious, but it matters for product comparison.

Two supplements supplying the same combined amount of EPA+DHA can still produce different fatty-acid exposures if their EPA and DHA proportions are substantially different.

What did the 2026 study find?

The researchers reported several ratio-dependent patterns.

EPA:DHA ratios below 1 — meaning relatively more DHA — were associated with the largest reductions in several cytokine measures in the pooled analysis.

Ratios of 1 or above — relatively more EPA — were more effective at increasing the EPA:DHA ratio in blood and reducing arachidonic acid.

The researchers also found that combined EPA+DHA exposure was associated with changes in several inflammatory biomarkers.

But there is an important limitation:

these are biomarker outcomes.

A lower CRP value or a different blood fatty-acid ratio is not automatically equivalent to fewer heart attacks, better cognition or another patient-important clinical outcome.

That distinction prevents an interesting mechanistic finding from becoming a much larger health claim than the study actually tested.

The ratio cannot be separated from the total dose

This is where supplement comparisons often become misleading.

Consider two fictional products:

Product A

• EPA: 600 mg
• DHA: 300 mg

Product B

• EPA: 300 mg
• DHA: 600 mg

Their ratios are very different.

But both provide:

900 mg combined EPA+DHA.

Now imagine a third product:

• EPA: 60 mg
• DHA: 30 mg.

It has the same 2:1 EPA:DHA ratio as Product A, but only 90 mg combined EPA+DHA.

Treating the ratio as the entire product specification would make those products look far more similar than they really are.

The ratio matters only in context.

EPA and DHA can produce somewhat different effects

A separate updated systematic review published in 2024 looked specifically at randomized trials directly comparing relatively pure EPA and DHA.

It included 24 publications from nine unique randomized controlled trials.

Both EPA and DHA lowered triglyceride concentrations.

The review concluded that DHA probably had a somewhat greater triglyceride-lowering effect in the available direct-comparison evidence.

DHA also appeared to have different effects on HDL cholesterol, LDL cholesterol, LDL particle size, heart rate and blood pressure.

But the researchers were explicit about an important weakness:

there are still relatively few high-quality trials that directly compare EPA with DHA across many outcomes.

That makes it difficult to turn these differences into a simple ranking.

“DHA changed LDL” needs context

One finding deserves particular care.

The direct-comparison review found that DHA could increase LDL cholesterol in some trials while also increasing LDL particle size.

Those observations should not be simplified into either:

“DHA raises bad cholesterol and is worse”

or:

“The LDL increase does not matter.”

Lipoprotein biology is more complicated than either statement.

More importantly, changes in individual risk markers should not automatically be used to predict the net effect of a supplement on long-term clinical outcomes.

For consumers comparing ordinary supplements, this is another reason to resist choosing an EPA:DHA ratio based on one isolated biomarker.

What about inflammation?

The 2026 analysis is especially interesting because it examined inflammatory markers across a much larger body of trials.

EPA+DHA supplementation was associated with reductions in markers including CRP, TNF-alpha and IL-6, particularly in participants with underlying health conditions.

Different ratios were associated with different pooled effects.

But inflammation is not one single condition.

CRP, TNF-alpha and IL-6 are biomarkers used in many research contexts.

A supplement changing one of those numbers does not mean it has been proven to treat every disease associated with inflammation.

The useful takeaway is narrower:

EPA:DHA composition appears capable of influencing measurable biological responses.

That is enough to justify recording the ratio.

It is not enough to declare a universal therapeutic ratio.

Do you need to calculate the EPA:DHA ratio yourself?

Usually, the raw amounts are more useful.

Suppose a label provides:

• EPA: 500 mg
• DHA: 250 mg.

That is a 2:1 EPA:DHA ratio.

The calculation is simple:

EPA amount divided by DHA amount.

But knowing the ratio should not replace recording:

• EPA per serving;
• DHA per serving;
• combined EPA+DHA;
• number of capsules or servings;
• total oil;
• source;
• cost.

Those fields tell you what the product actually supplies.

Why “1,000 mg fish oil” remains a poor comparison number

NIH notes that a typical 1,000 mg fish-oil supplement might provide around 180 mg EPA and 120 mg DHA, although products vary considerably.

That example illustrates the label problem.

A capsule containing 1,000 mg of fish oil does not necessarily contain 1,000 mg of EPA plus DHA.

Most of the oil can consist of other fatty acids and components.

That is why Bextera’s existing guide, Fish Oil Labels: Why 1,000 mg of Fish Oil Is Not 1,000 mg of EPA + DHA, focuses on the active fatty-acid quantities rather than total oil weight.

The same principle applies when comparing ratios.

First identify the actual EPA and DHA quantities.

Then interpret their relationship.

What about ALA?

ALA — alpha-linolenic acid — is another omega-3 fatty acid.

It is essential in the diet.

But ALA should not simply be added to EPA and DHA as though all three are directly interchangeable.

The body can convert ALA into EPA and then DHA, but NIH describes that conversion as limited.

That is why a product containing ALA from flax or another plant source cannot automatically be treated as providing the same EPA and DHA exposure as fish oil or an EPA/DHA-containing algal oil.

Again, the exact fatty acid matters.

Is an EPA-heavy supplement better?

Not universally.

Some clinical products and trials intentionally use EPA-heavy or EPA-only formulations for specific medical contexts.

That does not establish EPA-heavy supplements as the best general-purpose choice.

Likewise, DHA’s structural importance in certain tissues does not establish DHA-heavy products as universally superior.

The purpose of a supplement matters.

So do the population, outcome and total amount used in the supporting research.

This is particularly important when prescription omega-3 treatment is discussed.

Prescription products and medically managed high-dose protocols should not be treated as interchangeable with ordinary over-the-counter supplement use.

What should you compare on an omega-3 label?

Bextera’s preferred order is:

1. EPA per serving
2. DHA per serving
3. combined EPA+DHA
4. EPA:DHA ratio, when it is relevant to the question
5. total oil per serving
6. source, such as fish or algal oil
7. number of capsules required
8. cost per gram of EPA+DHA
9. independent testing information

This keeps the largest marketing number from becoming the most important number by default.

The takeaway

EPA and DHA belong to the same omega-3 family, but they should not be treated as identical ingredients.

The 2026 analysis of 96 clinical trials provides stronger evidence that the EPA:DHA ratio can influence blood fatty-acid and inflammatory-marker responses.

That makes the ratio a legitimate specification.

But it does not give consumers one perfect number to chase.

Different outcomes may respond differently. Direct head-to-head EPA-versus-DHA evidence remains limited for many questions. And biomarker changes should not automatically be translated into guaranteed clinical benefits.

For most supplement comparisons, the best starting point is still simpler:

How much EPA is there? How much DHA? How much combined EPA+DHA?

Once those numbers are clear, the ratio becomes useful context instead of another marketing shortcut.

Hero image: Oddman47 / Wikimedia Commons · CC0 1.0